Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.

Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, Schittenhelm J.

J Clin Pathol. 2014 Jul;67(7):556-61. doi: 10.1136/jclinpath-2013-202114. Epub 2014 Mar 7.

PMID:
24607494
2.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
3.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

4.

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K.

Int J Cancer. 2012 Sep 1;131(5):1104-13. doi: 10.1002/ijc.26499. Epub 2012 Jan 11.

5.

[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].

Wick W, Weller M.

Nervenarzt. 2010 Aug;81(8):928-30, 932-5. doi: 10.1007/s00115-010-2956-1. Review. German.

PMID:
20635074
6.

Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.

Jones DT, Mulholland SA, Pearson DM, Malley DS, Openshaw SW, Lambert SR, Liu L, Bäcklund LM, Ichimura K, Collins VP.

Acta Neuropathol. 2011 Jun;121(6):753-61. doi: 10.1007/s00401-011-0810-6. Epub 2011 Feb 17.

PMID:
21327941
7.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

8.

A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Idbaih A, Sanson M, Smitt PA, French PJ.

Clin Cancer Res. 2011 Nov 15;17(22):7148-55. doi: 10.1158/1078-0432.CCR-11-1274. Epub 2011 Sep 13.

9.

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM.

J Clin Oncol. 2009 Dec 10;27(35):5881-6. doi: 10.1200/JCO.2009.24.1034. Epub 2009 Nov 9.

10.

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].

PMID:
23015095
11.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.

PMID:
19636000
12.

O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.

Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T.

Int J Clin Oncol. 2010 Aug;15(4):352-8. doi: 10.1007/s10147-010-0065-6. Epub 2010 Mar 16.

PMID:
20232102
13.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
14.

Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.

Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R.

Mod Pathol. 2009 Dec;22(12):1600-11. doi: 10.1038/modpathol.2009.132. Epub 2009 Sep 18.

15.

Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):309-19. doi: 10.1007/s00401-015-1495-z. Epub 2015 Oct 22. Erratum in: Acta Neuropathol. 2016 Feb;131(2):321-2.

PMID:
26493382
16.

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.

Chin Med J (Engl). 2010 Dec;123(24):3566-73.

PMID:
22166632
17.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

PMID:
25427834
18.

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.

Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH.

Oncotarget. 2014 Sep 30;5(18):8083-92.

19.

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; Neuro-oncology Working Group (NOA) of the German Cancer Society..

Neuro Oncol. 2013 Aug;15(8):1017-26. doi: 10.1093/neuonc/not043. Epub 2013 Apr 17.

20.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

Supplemental Content

Support Center